...So Dietmar, thanks so much for joining us again. We really appreciate it. We saw a press release today, you've got an R&D Day on the 7th of December. So we don't have still your thunder, but we want to get your insights into what to -- how to think as we close out the year. But I guess at a sort of high level, I was going to ask you a little bit about IRA and I was going to ask you a little bit about the new Head of R&D. And if we can start there, and we'll sort of dive into more details. But there's been a lot of questions on IRA and how it might change the strategy of the various companies and areas like oncology, rare diseases, kind of vascular diseases, these are some of Sanofi strengths. And clearly, you're looking -- and you've been very active in terms of bringing on through [BD], different platforms and things like that, which might be impacted here as well. So how has it changed the way you think in your organization, things that are R&D from a strategy and from a prioritization...
